EAST INDIA PHARMACEUTICAL WORKS Unlisted Shares

East India Pharmaceutical Works Limited is a heritage generic pharmaceutical manufacturer producing a range of finished formulations — tablets, capsules, syrups, and injectables — for domestic distribution and export, with decades of manufacturing experience and established product approvals across multiple therapeutic categories. Unlisted shares are available through Valowth Capital — contact us for current pricing.

The Indian generic pharmaceutical industry is the backbone of affordable healthcare globally. India produces 20% of the world's generic drugs by volume, supplies 30% of the US generic drug market, and is the largest provider of generic medicines to the WHO's global vaccination programmes. Every generic medicine requires a qualified manufacturer — and East India Pharmaceutical Works' decades of manufacturing operations represent exactly the kind of established, validated manufacturing capacity that the industry needs.

Heritage pharmaceutical manufacturers carry unique competitive assets. Their manufacturing facilities have been inspected and validated by regulatory authorities — CDSCO in India, potentially USFDA or WHO-GMP for export — over many years. This validation status, which takes years to achieve and must be continuously maintained, is a genuine barrier to entry that newer manufacturers face significant time and cost to replicate.

Product approvals — the product registrations and marketing authorizations that allow a pharmaceutical company to sell specific medicines — accumulate over decades. Each approval represents regulatory investment that cannot easily be replicated. East India Pharmaceutical Works' portfolio of approved products across multiple therapeutic categories is a collection of valuable commercial licenses.

As India's generic pharmaceutical exports continue growing — driven by the global push for affordable medicines and the patent expiry cliff delivering new molecules for generic production — established manufacturers are well-positioned to capture international demand.

Valowth Capital facilitates verified demat-based transfer. Tax: LTCG (24+ months) = 20% with indexation. STCG = per slab.